Sam Brusco, Associate Editor01.03.24
SpineX has released results from its first in-human study treating a 60-year-old woman with cerebral palsy (CP).
The study was published in BioElectronic Medicine and showed “significant functional improvements” in an adult with CP after receiving treatment with the company’s non-surigcal, non-invasive SCiP therapy, which boasts U.S. Food and Drug Administration (FDA) breakthrough device status for CP treatment.
SCiP uses neuromodulation that acts as the spine’s “hearing aid,” amplifying the correct neural signals to help better control muscle movement. The company has been conducting clinical trials of its non-invasive therapy platforms that potentially could dramatically improve the lives of children living with CP. The SCiP device targets the abnormal connectivity between brain and spinal cord, to treat the root causes of CP.
After eight weeks of SCiP therapy, SpineX reported that the patient could perform daily living activities with minimal assistance. The study was led by Dr. Rahul Sachdeva, Ph.D. and Dr. Kristin Girshin, PT, DPT.
The patient has lived with CP her whole life. Despite living with this severely debilitating condition, she managed her symptoms with standard of care treatments. However, she consistently encountered limited mobility and spent a lot of energy completing routine tasks.
“After eight weeks of SCiP therapy, my balance was better, I was more confident in walking and climbing stairs with minimal assistance and was able to get dressed in less than half my usual time,” she said. “Over the years, I’ve tried every possible therapy available, but none of them had the impact that SCiP had, and in such a short period of time.”
“SCiP is a key missing piece in the puzzle for the treatment of CP,” added Dr. Girshin, lead therapist for the study and a key opinion leader in the CP community. “I am excited by the potential impact that SCiP could have on the CP population for both adults and children.”
In October, SpineX released results of SCiP therapy used on a nine-year-old girl.
The study was published in BioElectronic Medicine and showed “significant functional improvements” in an adult with CP after receiving treatment with the company’s non-surigcal, non-invasive SCiP therapy, which boasts U.S. Food and Drug Administration (FDA) breakthrough device status for CP treatment.
SCiP uses neuromodulation that acts as the spine’s “hearing aid,” amplifying the correct neural signals to help better control muscle movement. The company has been conducting clinical trials of its non-invasive therapy platforms that potentially could dramatically improve the lives of children living with CP. The SCiP device targets the abnormal connectivity between brain and spinal cord, to treat the root causes of CP.
After eight weeks of SCiP therapy, SpineX reported that the patient could perform daily living activities with minimal assistance. The study was led by Dr. Rahul Sachdeva, Ph.D. and Dr. Kristin Girshin, PT, DPT.
The patient has lived with CP her whole life. Despite living with this severely debilitating condition, she managed her symptoms with standard of care treatments. However, she consistently encountered limited mobility and spent a lot of energy completing routine tasks.
“After eight weeks of SCiP therapy, my balance was better, I was more confident in walking and climbing stairs with minimal assistance and was able to get dressed in less than half my usual time,” she said. “Over the years, I’ve tried every possible therapy available, but none of them had the impact that SCiP had, and in such a short period of time.”
“SCiP is a key missing piece in the puzzle for the treatment of CP,” added Dr. Girshin, lead therapist for the study and a key opinion leader in the CP community. “I am excited by the potential impact that SCiP could have on the CP population for both adults and children.”
In October, SpineX released results of SCiP therapy used on a nine-year-old girl.